Al-Obaidi arrives in Geneva for World Health Assembly
Kuwait's Minister of Health Dr. Ali Saad Al-Obaidi said Saturday the 69th session of the World Health Assembly will discuss a broad spectrum of highly important public health matters.
The meeting of the supreme decision-making body of the World Health Organization (WHO), due to take place here on May 23-28, will discuss a specific health agenda prepared by WHO Executive Board, determine the policies of the Organization, supervise financial policies, and review and approve the proposed program budget, he told KUNA.
Dr. Al-Obaidi made the comments upon his arrival at the Cointrin Airport here, leading a senior level delegation to the gathering.
"We will offer a presentation of the achievements made by Kuwait towards meeting the Millennium Development Goals (MDGs), notably the efforts to bring down the mortality rate of children below five years," he said.
"We will also present Kuwait's plans for comprehensive health coverage, enhancing the preparedness for combating communicable and nun-communicable diseases, and reaching higher rates of vaccinations of children," he went on.
"Kuwait has made headway in meeting the MDGs and implementing the 2030 Agenda for Sustainable Development," Dr. Al-Obaidi said.
"The tentative agenda, to be discussed in the second plenary session of the gathering, includes an item on monitoring of the achievement of the health-related Millennium Development Goals," he pointed out.
He added that the discussions will include draft global health sector strategies on response to communicable diseases such as HIV/AIDS, Ebola and viral hepatitis; and non-communicable diseases such as polio, childhood obesity, and the safety and accessibility of children's medication.
During the event, Kuwait will grant annual award of His Highness the Amir Sheikh Al-Ahmad Al-Jaber Al-Sabah for promotion of health which will be given to a Slovak physician this year.
The 69th session of the World Health Assembly will gather 3,500 health ministers from WHO member states, as well as representatives of government and non-government health-related agencies, medical research academies and pharmaceutical companies.